Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX +8.33% 3-Year EBITDA Growth Rate is 66.20% as of Dec. 2025, which is 48% above its 10-year median of 44.70. The stock has 4 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Imagion Biosystems ranks better than 92.81% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 66.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 49.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Imagion Biosystems was 66.20% per year. The lowest was -12.10% per year. And the median was 44.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Imagion Biosystems 3-Year EBITDA Growth Rate Related Terms
ASX:IBX vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Imagion Biosystems's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 66.20% mean?
Imagion Biosystems (ASX:IBX) has a 3-Year EBITDA Growth Rate of 66.20% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Imagion Biosystems and its competitors. This is 48% above median its historical median of 44.70. According to the industry distribution chart, Imagion Biosystems ranks #12 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 7.2%.
Is Imagion Biosystems' 3-Year EBITDA Growth Rate too high?
Imagion Biosystems' current 3-Year EBITDA Growth Rate of 66.20% is 48% above median its 10-year median of 44.70. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.10. Imagion Biosystems' value of 66.20% is 496.4% above this industry median. Based on the distribution chart, Imagion Biosystems ranks #12 out of 167 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Imagion Biosystems' 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #12 out of 167 companies for 3-Year EBITDA Growth Rate. This places Imagion Biosystems in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.10. Imagion Biosystems' value of 66.20% is 496.4% above this benchmark. While the company's 10-year median is 44.70 vs. the industry median of 11.10, Imagion Biosystems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.10, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imagion Biosystems's current 3-Year EBITDA Growth Rate of 66.20% is 496.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Imagion Biosystems and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current 3-Year EBITDA Growth Rate is 66.20%, which is 48% above median its own 10-year median of 44.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 98.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 66.20%, which is 48% above median its 10-year median of 44.70 and 496.4% above the Medical Diagnostics & Research industry median of 11.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current 3-Year EBITDA Growth Rate is 66.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
